Bioengineered Protein Drugs Market

ID: MRFR/Pharma/7520-HCR

100 Pages

Rahul Gotadki

October 2025

Bioengineered Protein Drug Market Research Report By Therapeutic Area (Oncology, Immunology, Metabolic Disorders, Neurological Disorders, Cardiovascular Diseases), By Type of Bioengineered Protein (Monoclonal Antibodies, Fusion Proteins, Enzymes, Hormones, Growth Factors), By Administration Route (Intravenous, Subcutaneous, Intramuscular, Intraperitoneal, Topical), By Expression System (Mammalian Cell Culture, Bacterial Expression, Yeast Expression, Plant Expression, Insect Cell Expression) and By Region - Forecast to 2035

Bioengineered Protein Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Certified Researchers

Customize Report

Bioengineered Protein Drugs Market Summary

The Global Bioengineered Protein Drug Market is projected to grow significantly from 0.37 USD Billion in 2024 to 0.98 USD Billion by 2035.

Key Market Trends & Highlights

Bioengineered Protein Drug Key Trends and Highlights

The market is expected to experience a compound annual growth rate (CAGR) of 10.13 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 1.07 USD Billion, indicating robust growth potential.
in 2024, the market is valued at 0.37 USD Billion, reflecting the current demand for bioengineered protein drugs.
Growing adoption of bioengineered therapies due to increasing prevalence of chronic diseases is a major market driver.

Bioengineered Protein Drugs Market

CAGR

9.24%

Market Size & Forecast

2024 Market Size	0.37 (USD Billion)
2035 Market Size	0.98 (USD Billion)
CAGR (2025-2035)	9.24%

Major Players

Eli Lilly and Company, Johnson & Johnson, AstraZeneca, Roche, Gilead Sciences, Sanofi, Biogen, Pfizer, Bristol Myers Squibb, Novartis, Celgene, AbbVie, Merck & Co., Amgen, Vertex Pharmaceuticals

Bioengineered Protein Drugs Market Trends

The bioengineered protein drug market is primarily driven by the rising prevalence of chronic diseases, advancements in biotechnology, and the increasing adoption of personalized medicine. As protein-based therapies offer targeted and effective treatment options for diseases like cancer, diabetes, and autoimmune disorders, there is a growing demand for these drugs.

Key opportunities in the bioengineered protein drug market include the development of novel protein-based therapies for unmet medical needs. The exploration of new delivery technologies, such as nanotechnology and antibody-drug conjugates, offers the potential to enhance drug efficacy and reduce side effects. Additionally, growing emphasis on precision medicine presents opportunities to develop customized therapies tailored to individual patients' genetic profiles.

Recent trends in the bioengineered protein drug market include the increasing adoption of monoclonal antibodies for a wide range of therapeutic applications. Another notable trend is the emergence of biosimilars, which are like existing biologics but offered at a lower cost, contributing to increased accessibility and affordability of these drugs.

The ongoing advancements in biotechnology are likely to drive the evolution of bioengineered protein drugs, enhancing therapeutic options and improving patient outcomes.

U.S. Food and Drug Administration (FDA)

Bioengineered Protein Drugs Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders is a primary driver of the Global Bioengineered Protein Drug Market Industry. As healthcare systems worldwide grapple with these conditions, the demand for innovative treatment options rises. Bioengineered protein drugs, known for their targeted therapeutic effects, are becoming essential in managing these diseases. For instance, monoclonal antibodies have shown efficacy in treating various cancers, leading to a projected market value of 0.37 USD Billion in 2024. This trend is expected to continue, with the market potentially reaching 1.07 USD Billion by 2035, reflecting a compound annual growth rate of 10.13% from 2025 to 2035.

Market Segment Insights

Bioengineered Protein Drug Market Therapeutic Area Insights

The therapeutic area segment is one of the central aspects to consider when investigating the Bioengineered Protein Drug Market landscape. Among the most prominent therapeutic areas that are spurring growth in the market and deserve attention in any analysis are oncology, immunology, metabolic disorders, neurological disorders, and cardiovascular diseases.

Oncology is the therapeutic area in which the development of treatments has been most affected by bioengineered protein drugs. The oncology segment is expected to reach a value of USD 267.4 billion by 2024, representing a significant share of the total market revenue. The growing demand for products of this type can be associated with the impressive progress in bioengineered protein drugs used for cancer treatment because of their effectiveness and minimal side effects.

Immunology is the segment with the value estimated at USD 125.6 billion by 2024, and this already demonstrates the interest of patients and the potential of the market. The use of protein-based therapies has enabled significant progress in managing a variety of immune-related diseases, including such common issues as autoimmune conditions, allergies, and various sources of inflammation.

Bioengineered proteins are also considered promising for the treatment of disorders, such as metabolic conditions, including diabetes and obesity. The use of drugs focused on these specific conditions is expected to result in a segment value of USD 67.2 billion by 2024 due to the growth of the prevalence of such conditions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Bioengineered Protein Drug Market Type of Bioengineered Protein Insights

The bioengineered protein drug market is segmented by type of bioengineered protein into monoclonal antibodies, fusion proteins, enzymes, hormones, and growth factors. Monoclonal antibodies are expected to hold the largest market share in 2023, due to their high specificity and affinity for target antigens, as well as the ability to modulate immune responses.

Fusion proteins is expected to be the fastest-growing segment, due to the ability to combine the functionalities of two or more proteins, offering superior functions and decreased immunogenicity. Enzymes are expected to have a significant market share, as they play a critical role in several biological procedures, while hormones and growth factors is expected to have a constant market share, as they play a critical role in the regulation of growth, development, and metabolism.

This is due to the increasing prevalence of chronic disorders, the growing adoption of customized treatments, and the advancements in bioengineering technology.

Bioengineered Protein Drug Market Administration Route Insights

The Bioengineered Protein Drug Market is segmented by administration route into intravenous, subcutaneous, intramuscular, intraperitoneal, and topical. Intravenous administration route held the largest market share in 2023 and is projected to continue its dominance throughout the forecast period.

The growth of this segment can be attributed to the increasing adoption of biologics and the convenience of intravenous administration. Bioengineered proteins are often administered intravenously due to their complex structure and high molecular weight, which can make oral or subcutaneous administration challenging. Intravenous administration allows for precise dosing and immediate delivery to the bloodstream.

However, intravenous administration requires trained healthcare professionals and can be associated with discomfort or side effects at the injection site.

Bioengineered Protein Drug Market Expression System Insights

The expression system segment is categorized based on the type of host organism used for protein production. In 2023, the mammalian cell culture segment held the largest market share due to its ability to produce complex proteins with high yields and post-translational modifications.

However, the bacterial expression segment is expected to witness significant growth over the forecast period (2023-2032), owing to its cost-effectiveness and scalability. Yeast expression, plant expression, and insect cell expression are other notable segments within the Expression segment.

Yeast Expression offers advantages in terms of scalability and low production costs, while Plant Expression provides the potential for producing large quantities of proteins in a cost-effective manner. This growth can be attributed to the increasing prevalence of chronic diseases, technological advancements in protein engineering, and rising demand for personalized medicine.

Get more detailed insights about Bioengineered Protein Drugs Market

Request Free Sample

Regional Insights

The Bioengineered Protein Drug Market is segmented into North America, Europe, APAC, South America, and MEA. North America dominates the market, capturing over 40% of the market share in 2023 due to the presence of major pharmaceutical companies and advanced healthcare infrastructure. Europe holds the second-largest share, driven by government initiatives and increasing investments in research and development.

APAC is expected to witness the fastest growth over the forecast period, owing to rising healthcare expenditure, growing awareness of bioengineered protein drugs, and expanding patient population. South America and MEA are expected to contribute a smaller share to the overall market due to limited healthcare infrastructure and lower adoption rates.

Bioengineered Protein Drug Market Regional Insights

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Key Players and Competitive Insights

Major players in the market are continuously focusing on research and development to expand their product portfolio and cater to unmet medical needs. For instance, in May 2023, Amgen announced the acquisition of ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases and cancer, to enhance its portfolio of inflammation and oncology therapies.

Leading players are also engaging in partnerships and collaborations to combine their expertise and capabilities to develop novel treatments. In March 2023, Eli Lilly and Company and Incyte entered a strategic collaboration to develop and commercialize baricitinib, a JAK1/2 inhibitor, for the treatment of various immune-mediated diseases, including rheumatoid arthritis and atopic dermatitis.

Amgen, Inc. is a leading player in the bioengineered protein drug market. The company has a strong focus on research and innovation and has a diverse portfolio of bioengineered protein drugs. Amgen's key products include Enbrel, Prolia, and Neulasta. The company has a broad global presence, and its products are commercialized in over 100 countries. Amgen is committed to developing innovative treatments that improve the lives of patients with serious diseases.

Roche Holding AG is a global healthcare company with a strong focus on oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The company has a track record of developing and commercializing innovative bioengineered protein drugs. Roche's key products include Avastin, Herceptin, and Rituxan. The company has a broad global presence, and its products are commercialized in over 100 countries. Roche is committed to developing innovative treatments that improve the lives of patients with serious diseases.

Key Companies in the Bioengineered Protein Drugs Market market include

Industry Developments

The Bioengineered Protein Drug Market is poised to witness substantial growth over the forecast period of 2024-2032. In 2023, the market was valued at approximately USD 326.22 billion, and it is projected to reach a valuation of USD 716.4 billion by 2032, exhibiting a CAGR of 9.13%. This growth can be attributed to factors such as the rising prevalence of chronic diseases, increasing adoption of personalized medicine, technological advancements in protein engineering, and supportive government policies.

Recent news developments include the approval of novel bioengineered protein drugs for various indications, strategic collaborations between pharmaceutical companies, and the expansion of manufacturing capacities to meet growing demand.

Future Outlook

Bioengineered Protein Drugs Market Future Outlook

The Bioengineered Protein Drug Market is poised for growth at a 9.24% CAGR from 2025 to 2035, driven by technological advancements, rising healthcare demands, and increasing investments in biopharmaceuticals.

New opportunities lie in:

Develop personalized protein drugs targeting specific genetic profiles.
Invest in AI-driven drug discovery platforms to enhance R&D efficiency.
Expand into emerging markets with tailored bioengineered solutions.

By 2035, the Bioengineered Protein Drug Market is expected to achieve substantial growth, solidifying its critical role in global healthcare.

Market Segmentation

Bioengineered Protein Drug Market Regional Outlook

North America
Europe
South America
Asia Pacific
Middle East and Africa

Bioengineered Protein Drug Market Therapeutic Area Outlook

Oncology
Immunology
Metabolic Disorders
Neurological Disorders
Cardiovascular Diseases

Bioengineered Protein Drug Market Expression System Outlook

Mammalian Cell Culture
Bacterial Expression
Yeast Expression
Plant Expression
Insect Cell Expression

Bioengineered Protein Drug Market Administration Route Outlook

Intravenous
Subcutaneous
Intramuscular
Intraperitoneal
Topical

Bioengineered Protein Drug Market Type of Bioengineered Protein Outlook

Monoclonal Antibodies
Fusion Proteins
Enzymes
Hormones
Growth Factors

Report Scope

Report Attribute/Metric	Details
Market Size 2024	0.37 (USD Billion)
Market Size 2035	0.98 (USD Billion)
Compound Annual Growth Rate (CAGR)	9.24% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019-2023
Market Forecast Units	USD Billion
Key Companies Profiled	Eli Lilly and Company, Johnson & Johnson, AstraZeneca, Roche, Gilead Sciences, Sanofi, Biogen, Pfizer, Bristol Myers Squibb, Novartis, Celgene, AbbVie, Merck Co, Amgen, Vertex Pharmaceuticals
Segments Covered	Therapeutic Area, Type of Bioengineered Protein, Administration Route, Expression System, Region
Key Market Opportunities	1. Growing Prevalence of Chronic Diseases 2. Advancements in Protein Engineering Technology 3. Increasing Demand for Personalized Medicine 4. Expansion of Emerging Markets 5. Government Initiatives for Healthcare Infrastructure
Key Market Dynamics	1. Rising Prevalence of Chronic Diseases 2. Technological Advancements 3. Increasing Government Support 4. Growing Demand for Personalized Medicine 5. Expanding Applications in Various Therapeutic Areas
Countries Covered	North America, Europe, APAC, South America, MEA
Market Size 2025	0.40 (USD Billion)

FAQs

What is the projected growth of the Bioengineered Protein Drug market?

The Bioengineered Protein Drug market is the expected increase in total market value of 0.98 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Bioengineered Protein Drug market?

Bioengineered Protein Drug market size was valued at approximately 0.37 billion USD in 2024. This figure will reach 0.98 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Bioengineered Protein Drug market?

Bioengineered Protein Drug market is expected to grow at a CAGR of 9.24% between 2025 and 2035.

How much will the Bioengineered Protein Drug market be worth by 2035?

Bioengineered Protein Drug market is expected to be worth of 0.98 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Bioengineered Protein Drug market perform over the next 10 years?

Over the next 10 years the Bioengineered Protein Drug market is expected to shift from usd billion 0.37 to 0.98 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the projected value of the Bioengineered Protein Drug Market in 2024?

The Bioengineered Protein Drug Market was valued at USD 0.33 billion in 2024.

Which regions are expected to dominate the Bioengineered Protein Drug Market?

North America and Europe are expected to dominate the Bioengineered Protein Drug Market throughout the forecast period.

What are the key applications of Bioengineered Protein Drugs?

Key applications of bioengineered protein drugs include the treatment of cancer, autoimmune disorders, and metabolic diseases.

Who are some of the key competitors in the Bioengineered Protein Drug Market?

Key competitors in the bioengineered protein drug market include Amgen, Roche, AbbVie, and Merck.

What are the major factors driving the growth of the Bioengineered Protein Drug Market?

Rising prevalence of chronic diseases, technological advancements, and supportive government policies are driving the growth of the bioengineered protein drug market.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓